5:28 PM
 | 
Sep 09, 2013
 |  BC Extra  |  Clinical News

Afferent's AF-219 meets in Phase II for chronic cough

Afferent Pharmaceuticals Inc. (San Mateo, Calif.) said twice-daily oral AF-219 met the primary endpoint in a Phase II trial to treat chronic cough. AF-219 reduced mean daytime cough frequency from baseline to week two as measured...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >